Fluidigm Stock Forecast for 2023 - 2025 - 2030
Updated on 02/04/2023


Fluidigm Stock Forecast and Price Target
The average price target for Fluidigm's stock set by recognized analysts recently is $1.77, which would result in a potential downside of approximately -91.27% if it reached this mark. The estimation is based on a high estimate of $1.98 and a low estimate of $1.58. Even if you are not interested in FLDM stock, it is still crucial to be aware of its competitors.
-91.27% Downside
Fluidigm Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $20.05 – an increase of 100.00%. The Fluidigm forecast is for Fair Value to reach $46.90 or grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ROG Stock Forecast | Roche Holding | Outperform |
5
|
CHF293.60 | Buy/Sell | CHF384.23 | 24.32% |
AVGO Stock Forecast | Broadcom | Outperform |
9
|
$597.62 | Buy/Sell | $654.63 | 10.27% |
TMO Stock Forecast | Thermo Fisher Scientific Inc | Outperform |
10
|
$587.76 | Buy/Sell | $618.99 | 5.49% |
DHR Stock Forecast | Danaher Corp | Outperform |
10
|
$269.85 | Buy/Sell | $304.24 | 12.84% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$111.79 | Buy/Sell | $120.97 | 11.82% |
Fluidigm Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's Revenue has increased by 11.38%, going from $117.24M to $130.58M. According to 0 analysts, Fluidigm's Revenue will fall by 1.18% in the next year, reaching $129.03M. Professionals believe that By 2030, Fluidigm's Revenue will fall to $129.34M – a 0.95% decrease from its current value.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SIE Stock Forecast | Siemens | Outperform |
6
|
145.02€ | Buy/Sell | 156.55€ | 6.88% |
BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$245.84 | Buy/Sell | $268.00 | 11.86% |
A Stock Forecast | Agilent Technologies | Outperform |
17
|
$154.55 | Buy/Sell | $162.50 | 7.73% |

.jpg)
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ILMN Stock Forecast | Illumina Inc | Outperform |
16
|
$214.26 | Buy/Sell | $254.08 | 16.45% |
PKI Stock Forecast | PerkinElmer | Outperform |
16
|
$138.56 | Buy/Sell | $159.83 | 17.28% |
TECH Stock Forecast | Bio-Techne | Buy |
16
|
$79.16 | Buy/Sell | $485.91 | 31.06% |
Fluidigm Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's Free Cash Flow has grown, increasing from $-37.74M to $-57.32M – a growth of 51.88%. For the following year, the 0 analysts predict that Fluidigm's Free Cash Flow will drop by 22.57%, reaching $-44.38M. In 2030, the professionals' prediction is that FLDM's Free Cash Flow will decrease by 19.82%, reaching $-45.96M.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BIO Stock Forecast | Bio-Rad Laboratories | Buy |
16
|
$470.88 | Buy/Sell | $588.75 | 23.70% |
BIM Stock Forecast | bioMérieux | Outperform |
18
|
96.70€ | Buy/Sell | 105.55€ | 11.17% |
QGEN Stock Forecast | QIAGEN N.V. | Outperform |
15
|
$49.54 | Buy/Sell | $0.00 | 11.02% |
Fluidigm Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's Net Income has decreased by 8.57%, going from $-64.79M to $-59.24M. In the next year, analysts expect Net Income to reach $-59.48M – an increase of 0.40%. For the next nine years, the forecast is for Net Income to grow by 0.10%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
QDEL Stock Forecast | Quidel | Outperform |
16
|
$85.61 | Buy/Sell | $126.20 | 46.01% |
TXG Stock Forecast | 10x Genomics | Outperform |
6
|
$47.84 | Buy/Sell | $0.00 | 109.03% |
4974 Stock Forecast | Takara Bio | Hold |
16
|
¥2.65k | Buy/Sell | ¥0.00 | -8.23% |
Fluidigm EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's EBITDA has grown by 12.98%, from $-45.93M to $-51.89M. In the following year, the 0 analysts surveyed believe that Fluidigm's EBITDA will decrease by 7.03%, reaching $-48.24M. According to professionals, by 2030, Fluidigm's EBITDA will have decreased by 6.57%, falling down to $-48.48M.
Fluidigm EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's EBIT has grown from $-50.54M to $-67.46M – a 33.48% increase. The next year, 0 experts forecast that Fluidigm's EBIT will decrease by 16.55%, reaching $-56.29M. In 2030, professionals predict that Fluidigm's EBIT will decrease by 14.75%, reaching $-57.51M.


Fluidigm EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Fluidigm's EPS has fallen from $-0.36 to $-0.35 – a 2.78% decrease. According to 0 analysts, Fluidigm's EPS will fall by 2.86% in the next year, reaching $-0.34. Professionals believe that By 2030, Fluidigm's EPS will fall to $-0.34 – a 3.00% decrease from its current value.